ZENITH-1 AND ZENITH-2: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS IN PROGRESS OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND F2/ F3 FIBROSIS (AASLD 2026) - Oct 6, 2026 - Abstract #3576; Pres time: Nov 7, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; P2, P3 | "The findings of the Phase 3 ZENITH-1 and ZENITH-2 trials will provide critical insights into the clinical efficacy, durability of response, and safety profile of efimosfermin alfa for the treatment of MASH with F2/F3 fibrosis. These trials will help inform future treatment strategies in MASH."
Clinical • P3 data • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • FGF21
|
|
Mazen Noureddin; Naga Chalasani; Meena Bansal; Jörn Schattenberg; Rohit Loomba; Arun Sanyal; Margaret James Koziel; Stuart Kendrick; Beth Ann Reedy; Patricia Mendez; Grace Dolman; Paul Lochhead; Laurent Castera
|